Why is Amneal expanding into GLP-1 drugs?

The GLP-1 market is experiencing explosive growth due to demand for drugs like Ozempic and Mounjaro, and Amneal aims to capitalize by offering lower-cost alternatives.

What risks does Amneal face in this expansion?

Amneal faces intense competition from giants like Novo Nordisk and Eli Lilly, as well as regulatory hurdles in obtaining approvals for biosimilars.

Amneal-Pfizer GLP-1 Deal: A New Growth Lever?

Amneal Pharmaceuticals (AMRX) is expanding into GLP-1 manufacturing and biosimilars through a partnership with Pfizer and acquisitions, aiming to strengthen its higher-value product strategy.

June 9, 2026

2 min read

Source: Zacks

Amneal Pharmaceuticals (AMRX) is expanding into GLP-1 manufacturing and biosimilars via a new partnership with Pfizer (PFE) and acquisitions, a move aimed at bolstering its shift toward higher-value products.

Partnership Details

Amneal has entered an agreement with Pfizer to manufacture GLP-1 drugs, a class of medications used for diabetes and obesity that has seen surging demand. Additionally, Amneal is acquiring manufacturing assets to boost its biosimilar capabilities.

Context

The move comes amid explosive growth in the GLP-1 market, led by drugs like Novo Nordisk's Ozempic and Wegovy and Eli Lilly's (LLY) Mounjaro. Amneal seeks to capitalize on this demand by offering lower-cost alternatives.

What It Means for Investors

The Pfizer partnership represents a strategic step for Amneal to diversify revenue and pivot toward higher-margin products. However, the GLP-1 market is highly competitive, and the company may face regulatory hurdles and intense competition from larger players.

Frequently Asked Questions

Amneal has entered an agreement with Pfizer to manufacture GLP-1 drugs, used for diabetes and obesity, as part of its strategy to expand into higher-value products.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.